Product Pathways - siRNA
SignalSilence® ABIN-1 siRNA I #6603
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western blot analysis of extracts from OVCAR8 cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® ABIN-1 siRNA I (+) or SignalSilence® ABIN-1 siRNA II #6609 (+), using ABIN-1 Antibody #4664 (upper) or β-Tubulin (9F3) Rabbit mAb #2128 (lower). The ABIN-1 Antibody confirms silencing of ABIN-1 expression, while the β-Tubulin (9F3) Rabbit mAb is used as a loading control.
SignalSilence® ABIN-1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit ABIN-1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
CST recommends transfection with 100 nM ABIN-1 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
The ABIN family (ABIN-1, -2, and -3) is a group of adaptor proteins that associate and cooperate with A20/TNFAIP3 (1), a ubiquitin editing protein that inhibits the key inflammatory transcription factor NF-κB (2-4). Mechanistically, A20 acts by regulating the ubiquitination of the kinase RIP, which leads to inhibition of the IKK complex (5).
- Verstrepen, L. et al. (2009) Biochem Pharmacol 78, 105-14.
- Beyaert, R. et al. (2000) Biochem Pharmacol 60, 1143-51.
- Lee, E.G. et al. (2000) Science 289, 2350-4.
- Dixit, V.M. et al. (1990) J Biol Chem 265, 2973-8.
- Wertz, I.E. et al. (2004) Nature 430, 694-9.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 6568 SignalSilence® Control siRNA (Unconjugated)
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6609 SignalSilence® ABIN-1 siRNA II
- 4664 ABIN-1 Antibody
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.